DDInter76 DDInter1652
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Amiodarone {u} (Compound) resembles {v} (Compound) Dronedarone
Amiodarone {u} (Compound) resembles {v} (Compound) Lucanthone
Amiodarone {u} (Compound) binds {v} (Gene) CACNA2D2
Amiodarone {u} (Compound) upregulates {v} (Gene) HMGCS1
Amiodarone {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Amiodarone {u} (Compound) downregulates {v} (Gene) PRPF4
Amiodarone {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Amiodarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liothyronine
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Amiodarone (Compound) resembles Dronedarone (Compound)
Amiodarone (Compound) resembles Lucanthone (Compound)
Amiodarone (Compound) binds CACNA2D2 (Gene)
Amiodarone (Compound) upregulates HMGCS1 (Gene)
Amiodarone (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Amiodarone (Compound) downregulates PRPF4 (Gene)
Amiodarone (Compound) causes Dermatitis exfoliative (Side Effect)
Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib